Indaptus Therapeutics (INDP) Financials

Indaptus Therapeutics (NASDAQ: INDP) remains a pre-revenue biotech with a heavy cash burn profile. Over the last several quarters, the company has consistently reported no revenue, ongoing operating losses, and reliance on financing to support its research and development efforts. The biggest takeaway from the latest quarter is that cash fell sharply while operating losses remained substantial.

• The company ended Q1 2026 with $1.5 million in cash and equivalents, giving it some near-term liquidity despite its limited resources.
• Q1 2026 operating losses improved versus Q4 2025, with operating expenses falling to $2.16 million from $8.16 million in the prior quarter.
• Net loss also narrowed sharply in Q1 2026 to $2.54 million from $8.11 million in Q4 2025, helped by lower spending.
• The company’s cash position has been supported by equity financing in prior quarters, which helps reduce immediate liquidity pressure.
• Indaptus continues to report no revenue, so performance is still entirely dependent on clinical progress and future capital raises.
• The balance sheet shows no debt at quarter-end in Q1 2026, which is favorable for a development-stage biotech.
• Shares outstanding have fluctuated meaningfully across periods, reflecting the company’s use of stock issuance as a funding source.
• Cash and equivalents dropped from $5.8 million in Q3 2025 to $1.5 million in Q1 2026, a steep decline in just two quarters.
• Q1 2026 operating cash flow was a negative $7.0 million, underscoring a high burn rate relative to the remaining cash balance.
• The company posted a negative equity balance in Q2 2025 before later financing restored equity, highlighting how fragile the balance sheet has been.

Longer-term trend: Indaptus has consistently burned cash for at least the last four years, with quarterly operating losses generally ranging from about $2.5 million to $5.2 million in 2025 and around $3.8 million to $4.6 million in early 2024. The company has repeatedly used share issuance to fund operations, which has helped sustain the business but also creates dilution risk for existing shareholders.

Bottom line: INDP remains a speculative biotech name. The latest quarter showed some improvement in spending discipline, but the company is still far from self-funding and will likely need additional capital if it does not secure meaningful clinical or partnership progress soon.